Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912497666> ?p ?o ?g. }
- W2912497666 endingPage "100009" @default.
- W2912497666 startingPage "100009" @default.
- W2912497666 abstract "The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG described live, attenuated, recombinant vesicular stomatitis virus (rVSV) as a chimeric virus vaccine for HIV-1 (Clarke et al., 2016). The rVSV vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological features of the rVSV vector system, followed by a template with details on the safety and characteristics of a rVSV vaccine against Zaire ebolavirus (ZEBOV). The rVSV-ZEBOV vaccine is a live, replication competent vector in which the VSV glycoprotein (G) gene is replaced with the glycoprotein (GP) gene of ZEBOV. Multiple copies of GP are expressed and assembled into the viral envelope responsible for inducing protective immunity. The vaccine (designated V920) was originally constructed by the National Microbiology Laboratory, Public Health Agency of Canada, further developed by NewLink Genetics Corp. and Merck & Co., and is now in final stages of registration by Merck. The vaccine is attenuated by deletion of the principal virulence factor of VSV (the G protein), which also removes the primary target for anti-vector immunity. The V920 vaccine caused no toxicities after intramuscular (IM) or intracranial injection of nonhuman primates and no reproductive or developmental toxicity in a rat model. In multiple studies, cynomolgus macaques immunized IM with a wide range of virus doses rapidly developed ZEBOV-specific antibodies measured in IgG ELISA and neutralization assays and were fully protected against lethal challenge with ZEBOV virus. Over 20,000 people have received the vaccine in clinical trials; the vaccine has proven to be safe and well tolerated. During the first few days after vaccination, many vaccinees experience a mild acute-phase reaction with fever, headache, myalgia, and arthralgia of short duration; this period is associated with a low-level viremia, activation of anti-viral genes, and increased levels of chemokines and cytokines. Oligoarthritis and rash appearing in the second week occur at a low incidence, and are typically mild-moderate in severity and self-limited. V920 vaccine was used in a Phase III efficacy trial during the West African Ebola epidemic in 2015, showing 100% protection against Ebola Virus Disease, and it has subsequently been deployed for emergency control of Ebola outbreaks in central Africa. The template provided here provides a comprehensive picture of the first rVSV vector to reach the final stage of development and to provide a solution to control of an alarming human disease." @default.
- W2912497666 created "2019-02-21" @default.
- W2912497666 creator A5004256871 @default.
- W2912497666 creator A5009138906 @default.
- W2912497666 creator A5010131062 @default.
- W2912497666 creator A5010176480 @default.
- W2912497666 creator A5023332141 @default.
- W2912497666 creator A5034754353 @default.
- W2912497666 creator A5047999206 @default.
- W2912497666 creator A5055066987 @default.
- W2912497666 creator A5058562937 @default.
- W2912497666 creator A5059368929 @default.
- W2912497666 creator A5065532410 @default.
- W2912497666 creator A5075394578 @default.
- W2912497666 creator A5080329476 @default.
- W2912497666 creator A5081829074 @default.
- W2912497666 creator A5086846734 @default.
- W2912497666 date "2019-04-01" @default.
- W2912497666 modified "2023-10-18" @default.
- W2912497666 title "rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment" @default.
- W2912497666 cites W145548758 @default.
- W2912497666 cites W1503660808 @default.
- W2912497666 cites W1521267370 @default.
- W2912497666 cites W1537984575 @default.
- W2912497666 cites W1607400635 @default.
- W2912497666 cites W1614627200 @default.
- W2912497666 cites W1814034318 @default.
- W2912497666 cites W1840025970 @default.
- W2912497666 cites W1898089896 @default.
- W2912497666 cites W1948693380 @default.
- W2912497666 cites W1965243869 @default.
- W2912497666 cites W1965916060 @default.
- W2912497666 cites W1971243173 @default.
- W2912497666 cites W1977240303 @default.
- W2912497666 cites W1995259721 @default.
- W2912497666 cites W2002821432 @default.
- W2912497666 cites W2003015789 @default.
- W2912497666 cites W2005392544 @default.
- W2912497666 cites W2008062430 @default.
- W2912497666 cites W2013346825 @default.
- W2912497666 cites W2014047151 @default.
- W2912497666 cites W2016230098 @default.
- W2912497666 cites W2019334516 @default.
- W2912497666 cites W2030292647 @default.
- W2912497666 cites W2035774172 @default.
- W2912497666 cites W2036199536 @default.
- W2912497666 cites W2036869628 @default.
- W2912497666 cites W2045795313 @default.
- W2912497666 cites W2046577658 @default.
- W2912497666 cites W2052207335 @default.
- W2912497666 cites W2059658426 @default.
- W2912497666 cites W2062661985 @default.
- W2912497666 cites W2067956486 @default.
- W2912497666 cites W2072823316 @default.
- W2912497666 cites W2073246940 @default.
- W2912497666 cites W2077661149 @default.
- W2912497666 cites W2081442068 @default.
- W2912497666 cites W2083015347 @default.
- W2912497666 cites W2083053620 @default.
- W2912497666 cites W2083214415 @default.
- W2912497666 cites W2083824233 @default.
- W2912497666 cites W2090633933 @default.
- W2912497666 cites W2093141813 @default.
- W2912497666 cites W2094513670 @default.
- W2912497666 cites W2095786128 @default.
- W2912497666 cites W2097246189 @default.
- W2912497666 cites W2098447112 @default.
- W2912497666 cites W2103992594 @default.
- W2912497666 cites W2104329250 @default.
- W2912497666 cites W2106522343 @default.
- W2912497666 cites W2110951885 @default.
- W2912497666 cites W2114242518 @default.
- W2912497666 cites W2119095733 @default.
- W2912497666 cites W2119680107 @default.
- W2912497666 cites W2123699288 @default.
- W2912497666 cites W2124603089 @default.
- W2912497666 cites W2125615308 @default.
- W2912497666 cites W2128953086 @default.
- W2912497666 cites W2130725649 @default.
- W2912497666 cites W2134567729 @default.
- W2912497666 cites W2135722581 @default.
- W2912497666 cites W2136978151 @default.
- W2912497666 cites W2138209294 @default.
- W2912497666 cites W2138294216 @default.
- W2912497666 cites W2138881713 @default.
- W2912497666 cites W2139914457 @default.
- W2912497666 cites W2141122594 @default.
- W2912497666 cites W2144902263 @default.
- W2912497666 cites W2146321329 @default.
- W2912497666 cites W2146500588 @default.
- W2912497666 cites W2146986766 @default.
- W2912497666 cites W2152076520 @default.
- W2912497666 cites W2153028137 @default.
- W2912497666 cites W2154189631 @default.
- W2912497666 cites W2158734363 @default.
- W2912497666 cites W2159409064 @default.
- W2912497666 cites W2162475821 @default.
- W2912497666 cites W2163549057 @default.